#SWEDEHEART
LightNews LightNews
ryangilbert.bsky.social
Sammy Swedeheart
Sam Ersson with the belt
February 9, 2025 at 3:34 AM
ryangilbert.bsky.social
Sammy Swedeheart!
February 18, 2025 at 3:44 AM
nicktheinventor.bsky.social
Other countries are sending people so high chance of meeting their Swedeheart
January 14, 2026 at 10:20 PM
jgrapsa.bsky.social
Percutaneous vs. surgical revascularisation of non-ST-segment elevation myocardial infarction with multivessel disease. Read the result of the SWEDEHEART registry in #EHJ 👉 bit.ly/3Oy0hZP #ESCjournals
Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry
AbstractBackground and Aims. The long-term outcomes of percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with
bit.ly
December 3, 2024 at 7:43 AM
jaccjournals.bsky.social
Myocardial infarction care pathways should implement early combination therapy with statins and #ezetimibe as standard care, because delaying use of combination LLT or using high-intensity statin monotherapy is associated with avoidable harm. www.jacc.org/doi/10.1016/...

#JACC #cvMI #SWEDEHEART
Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry:
www.jacc.org
April 18, 2025 at 7:17 PM
ryangilbert.bsky.social
Sammy Swedeheart is locked in.
October 11, 2025 at 11:45 PM
beansisprettygood.bsky.social
What a swedeheart
April 22, 2025 at 2:37 PM
hatateson.bsky.social
Okay, Swedeheart.
May 11, 2025 at 9:38 AM
accintouch.bsky.social
Routine screening for H. pylori infection during hospitalization 🏥 for acute #cvMI did not significantly reduce bleeding events or improve clinical outcomes, based on findings from the HELP-MI SWEDEHEART trial presented at #ESCCongress. Get the details: 🔗 https://bit.ly/41TgxMb
September 1, 2025 at 9:40 AM
moxcringe.bsky.social
That's you! A.... swedeheart 😔🥁
April 1, 2024 at 9:46 PM
danieljdrucker.bsky.social
A significantly higher risk of second-generation DES stent failure in individuals with #T1D followed by those with type 2 diabetes, compared with individuals without diabetes. This elevated risk was attributed to both in-stent restenosis and stent thrombosis🧪. diabetesjournals.org/care/article...
Coronary Stent Failure in Patients With Diabetes: A Nationwide Observational Study From SWEDEHEART
OBJECTIVE. The association between diabetes and coronary stent failure is poorly established with second-generation drug-eluting stents (DES). We aimed to
diabetesjournals.org
November 27, 2025 at 11:45 PM
castltrastondrs.medsky.network
#MedSky🧪#CardioSky Early Intervention on lowering of non-high-density lipoprotein cholesterol after #MI and prognosis: the SWEDEHEART registry. #LLT the earlier, the deeper, the longer, the better . Data which confirm the previous publication

academic.oup.com/eurheartj/ad...
Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry
AbstractBackground and aims. Non-high-density lipoprotein cholesterol (HDL-C) provides an estimate of lipid-associated risk and is a secondary treatment ta
academic.oup.com
September 2, 2024 at 5:22 PM
shanghai-ii.bsky.social
(2018年の記事ですね)
論文はこちら→ doi.org/10.1136/bmj....
December 24, 2025 at 11:04 AM
natrevcardiol.nature.com
New online! Role of Helicobacter pylori screening after myocardial infarction #CardioSky
Role of Helicobacter pylori screening after myocardial infarction
Nature Reviews Cardiology, Published online: 09 September 2025; doi:10.1038/s41569-025-01215-1Routine screening for Helicobacter pylori infection during hospitalization for myocardial infarction does not reduce the risk of upper gastrointestinal bleeding, according to findings from the HELP-MI SWEDEHEART trial, although secondary and subgroup analyses suggest potential clinically meaningful benefits.
bit.ly
September 9, 2025 at 4:29 PM
accintouch.bsky.social
🎥 Drs. Kusumoto and Rymer discuss interventional trials presented at #ESCCongress in Munich, including A-CLOSE and SWITCH SWEDEHEART.

More from ACC's coverage of the Congress here: https://bit.ly/4gAFan1

#cvACS #PCI #ACCAnywhere #CardioSky
August 30, 2026 at 8:46 AM
escardio.bsky.social
Does the addition of ezetimibe to high-intensity statin therapy early after MI associates with improved MACE?

Carlos Aguiar discusses critical data of the SWEDEHEART Registry on Cardiology This Week #ESCTVToday bit.ly/43hdQVA

Sign up for reminders so you Never Miss a Beat ow.ly/wqyK50VFfnx
May 6, 2025 at 8:23 AM
nejm.org
Among patients with acute coronary syndromes undergoing percutaneous coronary intervention, the risk of ischemic events was not lower with a default prasugrel policy than with a default ticagrelor policy. Full SWITCH-SWEDEHEART trial results: https://nej.md/4wGVCZd

#ESCCongress
A table showing the clinical end points at 1 year (intention-to-treat analysis). It compares two groups: Ticagrelor-Policy Group (9444 patients) and Prasugrel-Policy Group (7651 patients). Primary end point shows 1113 events in the Ticagrelor-Policy Group and 848 in the Prasugrel-Policy Group. Secondary end points are listed, including death from any cause, myocardial infarction, stroke, major bleeding, and stent thrombosis, with corresponding patient numbers and percentages for each group. Odds ratios with confidence intervals are provided.
August 29, 2026 at 9:35 AM
tctmd.bsky.social
Results from SWITCH-SWEDEHEART suggest that a prasugrel-first approach may improve outcomes for patients with ACS undergoing PCI. For more on the findings presented by Elmir Omerovic today at #ESCCongress: www.tctmd.com/news/prasugr...
Prasugrel by Default in ACS Patients Post-PCI Lowers Bleeding With No Ischemic Penalty
SWITCH-SWEDEHEART’s unique design randomized healthcare regions but wasn’t a head-to-head comparison with ticagrelor.
www.tctmd.com
August 29, 2026 at 7:24 PM
cboyer.bsky.social
Also frontier seems to be concurrent prospective trial plus observational study (although obviously this has been around forever eg WHI) pmc.ncbi.nlm.nih.gov/articles/PMC...
Prospective benchmarking of an observational analysis in the SWEDEHEART registry against the REDUCE-AMI randomized trial
Prospective benchmarking of an observational analysis against a randomized trial increases confidence in the benchmarking process as it relies exclusively on aligning the protocol of the trial and the...
pmc.ncbi.nlm.nih.gov
August 12, 2025 at 11:01 AM
ordofibonacci.bsky.social
Hot Line 5: Remote Exercise SWEDEHEART trial. What were the results?
Maria Back (Sahlgrenska University Hospital - Gothenburg, Sweden).
European Society of Cardiology
youtu.be/wmSWNNuC8Ic?...
Hot Line 5: Remote Exercise SWEDEHEART trial. What were the results?
YouTube video by European Society of Cardiology
youtu.be
September 8, 2026 at 10:46 PM
nejm.org
Original Article: Prasugrel versus Ticagrelor in Acute Coronary Syndromes (SWITCH-SWEDEHEART trial) nej.md/4wGVCZd
A table showing the clinical end points at 1 year (intention-to-treat analysis). It compares two groups: Ticagrelor-Policy Group (9444 patients) and Prasugrel-Policy Group (7651 patients). Primary end point shows 1113 events in the Ticagrelor-Policy Group and 848 in the Prasugrel-Policy Group. Secondary end points are listed, including death from any cause, myocardial infarction, stroke, major bleeding, and stent thrombosis, with corresponding patient numbers and percentages for each group. Odds ratios with confidence intervals are provided.
August 31, 2026 at 7:34 PM
medicalxpress.com.web.brid.gy
Trial results favor prasugrel over ticagrelor after coronary stenting
Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.
medicalxpress.com
August 31, 2026 at 3:56 PM
tctmd.bsky.social
From #ESCCongress, @mmamas1973.bsky.social, Elmir Omerovic, and Jurriën ten Berg discuss findings from the SWITCH-SWEDEHEART trial. Watch the full video: www.tctmd.com/videos/beyon...
August 29, 2026 at 6:21 PM
herzmedizin.bsky.social
✨ #ESCCongress 2026: Optimale antithrombotische Therapie nach ACS
🔬 4 Studien: PREMIUM/SWITCH SWEDEHEART/A-CLOSE/EPIDAURUS
🎙️ Prof. Gaku Nakazawa präsentierte die Daten.
🔍 Prof. Tommaso Gori ordnet die Ergebnisse ein.
➡️ herzmedizin.de/fuer-aerzte-...
#DGK #Kardiologie
PREMIUM/SWITCH SWEDEHEART/A-CLOSE/EPIDAURUS | ESC Congress 2026
ESC 2026 | PREMIUM/SWITCH SWEDEHEART/A-CLOSE/EPIDAURUS: 4 Studien zur antithrombotischen Therapie. Von Prof. T. Gori.
herzmedizin.de
August 29, 2026 at 3:44 PM
womenasone.bsky.social
Today we're celebrating 2026 Mentorship Award mentor Jessica Schubert, MD, PhD.

A specialist in clinical pharmacology, her work has advanced our understanding of lipid-lowering therapy, treatment adherence, and sex differences in cardiovascular care.

#WomenAsOneAwards #CardioSky
Jessica Schubert, MD, PhD, 2026 Award winner - Mentor. Mentorship pairing #3: Adherence to lipid-lowering therapy in women. A clinical pharmacology specialist at Uppsala University Hospital and researcher at Uppsala University, Sweden. Her research focuses on lipid-lowering therapy and secondary prevention after myocardial infarction, with particular interest in sex differences in treatment adherence and cardiovascular outcomes. Using nationwide registries, including SWEDEHEART, she studies atherogenic lipoproteins, lipid-lowering therapy, and long-term outcomes after acute coronary syndrome. Her research has informed recent European cardiovascular guidelines and clinical practice. She also serves on the editorial board of the European Heart Journal - Cardiovascular Pharmacotherapy. Sponsored by Daiichi Sankyo Europe.
August 1, 2026 at 3:00 PM